HOPA is committed providing high quality education that is strongly integrated with HOPA’s core passion to support pharmacy practitioners and promote and advance Hematology/Oncology Pharmacy to optimize the care of individuals affected by cancer. HOPA strives to become the destination of choice for quality education focused on creating competent hematology/oncology pharmacists with sound domain knowledge, skills and managerial acumen.  Below is the full spectrum of education offerings – you may also sort by content area, date, delivery method, and if it offers BCOP recertification credit.

Case Study: VOD With Renal and Pulmonary Dysfunction in an Adult Patient With AML Following HSCT

Jazz Pharmaceuticals Webinar

Please join us for a live, 1-hour webinar to gain a better understanding of veno-occlusive disease (VOD) with renal or pulmonary dysfunction post HSCT (hematopoietic stem-cell transplantation), and treatment with Defitelio® (defibrotide sodium).

Learning Objectives

  • Improve the understanding of the pathogenesis of VOD and its potential to become life-threatening
  • Heighten vigilance to proactively identify patients with risk factors for VOD
  • Discuss strategies for earlier detection of VOD post HSCT and increase confidence in making the diagnosis
  • Review the proposed mechanism of action, clinical efficacy, and safety

Date and Time

Tuesday, September 24, 2019
8:00–9:00 pm EDT / 7:00–8:00 pm CDT/ 5:00–6:00 pm PDT

Register Now


Monank Patel, PharmD BCOP
Clinical Pharmacy Specialist
Bone Marrow Transplant and Hematology/Oncology
Allegheny Health Network
Pittsburgh, PA


  • You will receive a final confirmation and instructions upon registration.
  • This free event is hosted by the Hematology/Oncology Pharmacy Association (HOPA) and is open to HOPA members and nonmembers.
  • Please note: There are no certified continuing education credits approved for this program. 


Defitelio is indicated for the treatment of adult and pediatric patients with hepatic VOD, also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following HSCT.


Defitelio is contraindicated in the following conditions:

  • Concomitant administration with systemic anticoagulant or fibrinolytic therapy
  • Known hypersensitivity to Defitelio or to any of its excipients

Warnings and Precautions

Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.

Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.

Hypersensitivity Reactions
Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.

Most Common Adverse Reactions
The most common adverse reactions (incidence ≥10% and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.

Please click here to see the full Prescribing Information for Defitelio.

Defitelio logo resized